sC5b-9 Antibody (Monoclonal - neoantigen)

A murine monoclonal antibody to a neoantigen on the terminal complement complex.

Product Specifications

Citations	27
Clonality	Monoclonal
Immnogen	Purified human protein.
Applications	See citations and technical data sheet for application info.
Concentration	1.0-1.2 mg/mL
Conjugate	Unconjugated
Cross Reactivity	Human, Baboon, Cynomologus macaque, Rhesus macaque.

Technical Documents

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.

Catalog Number	A239
Catalog Number (CE)	N/A
Size	100 µl
Price (USD)	$365.00
Price (EURO)	330,00 €

Request an Order

Contact us

US Phone	+1 (858) 552 1100
EU Phone	+353 (91) 412 474
US Email	contact-us@quidelortho.com
EU Email	contact-emea@quidelortho.com

Specifications
Citations
Certificate of Analysis

Specifications

Description	A murine monoclonal antibody to a neoantigen on the terminal complement complex.
Size	100 µl
Concentration	1.0-1.2 mg/mL
Applications	See citations and technical data sheet for application info.
Form	Liquid. Borate Buffered Saline (pH 8.4 ± 0.2), with ≤ 0.1% Sodium Azide.
Clonality	Monoclonal
Immunogen	Purified human protein.
Conjugate	Unconjugated
Cross Reactivity	Human, Baboon, Cynomologus macaque, Rhesus macaque.
Isotype	IgG2bk
Purity	≥ 95% by SDS PAGE
Source	Mouse
Specificity	This monoclonal antibody was raised against purified human C9. This antibody has been shown to bind to a neoantigen expressed on SC5b-9, TCC, MAC, poly- C9 and on denatured immobilized C9.
Storage	Short term (30 days) 4˚C. Long term at or below –20˚C.
Background	The Terminal Complement Complex (TCC, SC5b-9) is generated by the assembly of C5 through C9 as a consequence of activation of the complement system by either the classical, lectin or alternative pathway. The membrane attack complex (MAC), a form of TCC, is a stable complex that mediates the irreversible target cell membrane damage associated with complement activation. Complexes formed in the absence of a target membrane bind to naturally occurring regulatory serum proteins, e.g. the S protein, at the C5b-7 stage of assembly forming soluble, non-lytic TCC.

Citations

Title	Year	Applications	Sample Species	Sample	Sample Details
Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney.	2022	ELISA	Human	Plasma	Antibody Mediated Rejection
CipA mediates complement resistance of Acinetobacter baumannii by formation of a factor I-dependent quadripartite assemblage.	2022	ELISA	Human	Serum	CipA
Inflammasome-Dependent Peroxiredoxin 2 Secretion Induces the Classical Complement Pathway Activation.	2021	Complement Activation Assay, WB	Human	Serum	N/A
The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare.	2021	ELISA	Human	Plasma	Lupus Nephritis
Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients.	2021	ELISA	Human	Plasma	N/A
Interleukin-1β and cathepsin D modulate formation of the terminal complement complex in cultured human disc tissue.	2021	IHC	Human	Disc Tissue	N/A
Placental Complement Activation in Fetal and Neonatal Alloimmune Thrombocytopenia: An Observational Study.	2021	IHC	Human	Placenta Tissue	N/A
Establishing a Case for Anti-complement Therapy in Membranous Nephropathy.	2020	ELISA	Human	Urine	Membranous Nephropathy
EGFR modulates complement activation in head and neck squamous cell carcinoma.	2020	IF	Cell Culture	HNSCC Cells	N/A
Terminal complement complex formation is associated with intervertebral disc degeneration.	2020	IHC	Human	Spinal Cord Tissue	N/A
A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the Staphylococcus aureus SSL7 Protein.	2018	ELISA	Human	Serum	N/A
Inhibition of Immune Complex Complement Activation and Neutrophil Extracellular Trap Formation by Peptide Inhibitor of Complement C1.	2018	ELISA	Human	Serum	N/A
High-Mobility Group Box 1-Induced Complement Activation Causes Sterile Inflammation.	2018	ELISA, IF	Human	Serum	HMGB1-coated microplates
The Plasmodium falciparum blood stages acquire factor H family proteins to evade destruction by human complement	2016	IF, WB	Cell Culture	Plasmodium falciparum culture	N/A
The Plasmodium falciparum blood stages acquire factor H family proteins to evade destruction by human complement	2016	IF, WB	Human	Red Blood Cells	Plasmodium falciparum incubated
Genetic engineering strategies to prevent the effects of antibody and complement on xenogeneic chondrocytes	2015	FC	Porcine	Articular chondrocytes	N/A
The Local Complement Activation on Vascular Bed of Patients with Systemic Sclerosis: A Hypothesis-Generating Study	2015	IF	Human	Skin Tissue	N/A
Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy	2015	IHC	Human	Kidney Tissue	Thrombotic Microangiopathy
CspA from Borrelia burgdorferi inhibits the terminal complement pathway.	2013	IF	Bacteria	Borrelia burgdorferi	N/A
Borrelia valaisiana resist complement-mediated killing independently of the recruitment of immune regulators and inactivation of complement components	2013	IF	Bacteria	Borrelia valaisiana	N/A
Complement Activation on Platelets Correlates with a Decrease in Circulating Immature Platelets in Patients with Immune Thrombocytopenic Purpura	2009	ELISA	Human	Plasma	N/A
Characterization of early and terminal complement proteins associated with polymorphonuclear leukocytes in vitro and in vivo after spinal cord injury.	2008	FC, IF	Rat	Spinal Cord Tissue	N/A
The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro	2008	IF	Human	Placenta Tissue	N/A
Binding of vitronectin by the Moraxella catarrhalis UspA2 protein interferes with late stages of the complement cascade	2006	WB	Human	Serum	Moraxella catarrhalis
Activation of early components of complement targets myelin and oligodendrocytes in the aged rhesus monkey brain.	2005	IHC	Rhesus Monkey	Brain Tissue	N/A
Killing of dsrA mutants of Haemophilus ducreyi by normal human serum occurs via the classical complement pathway and is initiated by immunoglobulin M binding	2005	Radiation Immunoassay	Human	Serum	Haemophilus ducreyi incubated
Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide.	1998	ELISA	Human	Amyloid-βeta peptides & NHS	N/A

Certificate of Analysis

Showing results for

No results found for